[Nature] Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial

 关闭 求助已关闭
JasonZheng 发表于 2026-7-28 22:23:39 | 显示全部楼层 |阅读模式
悬赏10积分

期刊:Nature Medicine

文献作者:Irene L. M. Reijers; Alexander M. Menzies; Alexander C. J. van Akkooi; Judith M. Versluis; Noelle M. J. van den Heuvel; Robyn P. M. Saw; Thomas E. Pennington; Ellen Kapiteijn; Astrid A. M. van der Veldt; Karijn P. M. Suijkerbuijk; Geke A. P. Hospers; Elisa A. Rozeman; Willem M. C. Klop; Winan J. van Houdt; Karolina Sikorska; Jos A. van der Hage; Dirk J. Grünhagen; Michel W. Wouters; Arjen J. Witkamp; Charlotte L. Zuur; Judith M. Lijnsvelt; Alejandro Torres Acosta; Lindsay G. Grijpink-Ongering; Maria Gonzalez; Katarzyna Józwiak; Carolien Bierman; Kerwin F. Shannon; Sydney Ch’ng; Andrew J. Colebatch; Andrew J. Spillane; John B. A. G. Haanen; Robert V. Rawson; Bart A. van de Wiel; Lonneke V. van de Poll-Franse; Richard A. Scolyer; Annelies H. Boekhout; Georgina V. Long; Christian U. Blank

出版日期:2022-6-

DOI号:10.1038/s41591-022-01851-x

下载链接:https://www.nature.com/articles/s41591-022-01851-x.pdf

文献链接:https://doi.org/10.1038/s41591-022-01851-x

当前文献来源于 Springer Science and Business Media LLC


备注信息:

已采纳

附件内容

查看完整内容

全部回复1 显示全部楼层
学术小白P 发表于 2026-7-28 22:23:40 | 显示全部楼层

当前求助已完成,请重新发起求助。

已完结状态的附件将会在24小时内删除。
返回列表